Assay of oxidized fibrinogen reactivity (OFR) as a biomarker of oxidative stress in human plasma: the role of lysine analogs.

Background: There is accumulating evidence that fibrinogen is also a biomarker of oxidative stress in human plasma. Results of in vitro studies demonstrated that fibrinogen can bind to apolipoprotein(a) [apo(a)] component of lipoprotein(a) [Lp(a)] through both lysine-sensitive and lysine-insensitive mechanisms. The goal of the present study was to investigate oxidized fibrinogen reactivity (OFR) as a biomarker of oxidative stress in human plasma in the presence and absence of lysine analogs.

Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels.

In 1996 a novel oxidative stress biomarker, referred to as advanced oxidation protein products (AOPP) was detected in the plasma of chronic uremic patients. The aim of the present studies was to find out that which plasma fraction(s) is responsible for AOPP reactivity. Thermal treatment of pooled samples of human citrate-plasma or EDTA-plasma at 50 degrees C resulted in a rapid and parallel loss of fibrinogen concentration and AOPP reactivity.

Antioxidant capacity of the human pericardial fluid: does gender have a role?

The aim of the present study was to assess the antioxidant capacity in the serum and pericardial fluid of patients undergoing heart surgery for coronary heart disease (CHD) or valvular heart disease (VHD) and to find out whether there are gender-related differences in the antioxidant defense. This study involved 85 patients (35 VHD and 50 CHD) undergoing elective heart surgery. Blood samples from the peripheral vein and from the pericardial fluid were taken intraoperatively.

Impairment of blood-brain barrier integrity during carotid surgery as assessed by serum S-100B protein concentrations.

During carotid endarterectomy (CEA) the internal carotid artery is cross-clamped for a period of several minutes. This maneuver may cause cerebral hypoperfusion and/or impairment of the blood-brain barrier (BBB) even in cases where clinical signs are absent. The aim of the present study was to examine whether such alterations could be detected by monitoring the cerebral marker S-100B protein concentrations during and after CEA in the serum.